DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w4qp4d/pharmapoint) has announced the addition of the "Postmenopausal Vaginal Atrophy - Spain Drug Forecast and Market Analysis to 2022" report to their offering.
Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, it is expected to undergo a considerable change between 2012 and 2022. This market has historically had a large untreated population due to: low diagnosis rates, safety issues with the existing therapies, and poor patient compliance. Since the mainstay estrogen-based therapies are associated with causing elevated risk for breast cancer, endometrial cancer, and stroke, many women go untreated.
Historically, there exists a high level of brand loyalty among Spanish patients. As a result, this market will see much lower generic erosion than the US and German markets. Spain's PVA market will face temperate generic erosion, as Teva's Colpotrofin cream and Colpotrofin vaginal tablet lose patent protection in 2015. Late in the forecast period, this market will see Vagifem's loss of patent exclusivity in 2020.
Scope
- Overview of PVA including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Spain PVA market.
Key Topics Covered:
1 Table of Contents
2 Introduction
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Symptoms
4 Disease Management
4.1 Treatment Overview
4.2 Treatment Guidelines
4.3 Disease Management
4.4 Spain
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
6 Opportunity and Unmet Needs
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 Market Outlook
9 Appendix
For more information visit http://www.researchandmarkets.com/research/w4qp4d/pharmapoint
